Real-world challenges for hepatitis C virus medications: a critical overview.

about

Real-world challenges for hepatitis C virus medications: a critical overview.

Item

http://www.wikidata.org/entity/Q39326974

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Real-world challenges for hepatitis C virus medications: a critical overview.

@en

Real-world challenges for hepatitis C virus medications: a critical overview.

@nl

type

Item

label

Real-world challenges for hepatitis C virus medications: a critical overview.

@en

Real-world challenges for hepatitis C virus medications: a critical overview.

@nl

prefLabel

Real-world challenges for hepatitis C virus medications: a critical overview.

@en

Real-world challenges for hepatitis C virus medications: a critical overview.

@nl

P1476

Real-world challenges for hepatitis C virus medications: a critical overview.

@en

P2093

Imran Shahid

http://www.w3.org/2001/XMLSchema#string

Muhammad Hassan Hafeez

http://www.w3.org/2001/XMLSchema#string

Sajida Hassan

http://www.w3.org/2001/XMLSchema#string

Waleed Hassan AlMalki

http://www.w3.org/2001/XMLSchema#string

P2860

Extrahepatic manifestations of chronic hepatitis C virus infection

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals

Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population

Evasion of intracellular host defence by hepatitis C virus

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

P304

1-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1040841X.2017.1329277

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28539069

http://www.w3.org/2001/XMLSchema#string